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ABSTRACT
Objective Different lines of evidence have highlighted
the role of IL-17A in the inﬂammatory process occurring
in giant cell arteritis (GCA). The aim of the present study
was to assess whether the IL17A locus inﬂuences GCA
susceptibility and its clinical subphenotypes.
Methods We carried out a large meta-analysis
including a total of 1266 biopsy-proven GCA patients
and 3779 healthy controls from four European
populations (Spain, Italy, Germany and Norway). Five
IL17A polymorphisms (rs4711998, rs8193036,
rs3819024, rs2275913 and rs7747909) were selected
by tagging and genotyped using TaqMan assays. Allelic
combination and dependency tests were also performed.
Results In the pooled analysis, two of the ﬁve analysed
polymorphisms showed evidence of association with
GCA (rs2275913: PMH=1.85E−03, OR=1.17 (1.06–
1.29); rs7747909: PMH=8.49E–03, OR=1.15 (1.04–
1.27)). A clear trend of association was also found for
the rs4711998 variant (PMH=0.059, OR=1.11 (1.00–
1.23)). An independent effect of rs2275913 and
rs4711998 was evident by conditional regression
analysis. In addition, the haplotype harbouring the risk
alleles better explained the observed association than
the polymorphisms independently (likelihood p value
<10−05).
Conclusions Polymorphisms within the IL17A locus
show a novel association with GCA. This ﬁnding
supports the relevant role of the Th17 cells in this
vasculitis pathophysiology.
INTRODUCTION
Giant cell arteritis (GCA) is a systemic vasculitis
with speciﬁc involvement of the aorta and external
carotid arteries and their branches. Lesions are
characterised by appearance of multinucleated giant
cells, fragmented internal elastic lamina and cellular
inﬁltrates, mainly macrophages and T lympho-
cytes.1 GCA affects predominantly women and
people generally older than 50 years, representing
the most frequent vasculitis in elderly individuals
from Western countries.2
Traditionally, GCA has been considered as a
Th1-mediated disease based on granuloma forma-
tion and high levels of IFN-γ; however, Th17 cells
are also present in GCA lesions.3 Th17 cells are
characterised by the secretion of IL-17, a cytokine
leading to proinﬂammatory responses that partici-
pate in the pathogenic mechanisms of several auto-
immune diseases.4 Interestingly, a recent study has
showed that the number of Th17 lymphocytes is
signiﬁcantly increased in patients with GCA, result-
ing in an imbalance between Th17 and regulatory
T cells.5 In addition, an increased expression of
IL-17A3 6 and several cytokines that participate in
Th17 differentiation and maintenance has been
detected in temporal artery samples from patients
with GCA.7 8 On the other hand, studies in animal
models have shown that mice deﬁcient in inter-
feron regulatory factor 4 (IRF4) binding protein,
which inhibits IL-17A production, develop a large-
vessel vasculitis due to an inappropriate production
of this cytokine.9 These observations indicate that
Th17 cells play a critical role in the inﬂammatory
process occurring in GCA.
In recent years, several genes have been proposed
to inﬂuence GCA susceptibility,10 some of which
have highlighted the relevant role of Tcells in its pre-
disposition, such as HLA-DRB1 or PTPN22.10 11
However, the overall genetic component of this con-
dition remains unknown yet.
Considering this proposed crucial role of Th17
cells in GCA, we aimed to assess whether poly-
morphisms at the IL17A gene are involved in the
genetic predisposition to this vasculitis and its clin-
ical subgroups.
METHODS
Study population
A total of 1266 patients with GCA and 3779 unre-
lated controls from four European cohorts were
analysed, comprising a discovery set from Spain
(931 cases and 1845 controls) and three independ-
ent sets from Italy (178 cases and 1175 controls),
Germany (74 cases and 480 controls) and Norway
(83 cases and 279 controls). Online supplementary
table S1 summarises the main characteristics of the
analysed cohorts. Case/control sets were matched
by geographical origin and ethnicity. All patients
had a positive temporal artery biopsy and fulﬁlled
the 1990 American College of Rheumatology
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classiﬁcation criteria.12 Patients were stratiﬁed according to the
presence or absence of polymyalgia rheumatica, visual ischaemic
manifestations and irreversible occlusive disease, as previously
described.11
Genotyping methods
Genomic DNA was extracted from peripheral white blood cells
using standard procedures. We analysed ﬁve single-nucleotide
polymorphisms (SNPs) located within IL17A, which tag over
86% of the variability of this locus as described elsewhere.13
The rs4711998, rs8193036, rs3819024, rs2275913 and
rs7747909 SNPs were genotyped using TaqMan allelic discrim-
ination assays on a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, California, USA).
Statistical analysis
Online supplementary table S2 shows the overall statistical
power of the analysis (http://www.sph.umich.edu/csg/abecasis/
CaTS/). Plink (V.1.07) (http://pngu.mgh.harvard.edu/purcell/
plink/) and StatsDirect V.2.6.6 (StatsDirect Ltd, Cheshire, UK)
were used to perform 2×2 contingency tables and χ2 test. ORs
and 95% CIs were obtained according to Woolf ’s method.
Permutation test (10 000 permutations) was performed to esti-
mate empirical p values (PEMP1, uncorrected p value; PEMP2,
corrected for multiple testing) as implemented in Plink. p Values
<0.05 were considered statistically signiﬁcant. Dependency of
association between SNPs was determined by conditional logis-
tic regression analysis as implemented in Plink and the allelic
combinations were tested using Haploview (V.4.2). The good-
ness of ﬁt of both haplotype and independent SNP models was
compared using Plink. The analysis of the combined data from
all populations was performed using Plink and StatsDirect.
Breslow-Day (BD) test was used to estimate the homogeneity
among populations. Pooled analyses were performed by
Mantel–Haenszel (MH) test under ﬁxed effects.
RESULTS
Genotypic frequencies did not deviate from Hardy-Weinberg
equilibrium (p>0.01), and the genotype success rate was
>95%.
Allele test
First, we analysed the IL17A polymorphisms in the Spanish
cohort (table 1). The case/control analysis yielded an association
between rs2275913 (p=0.011, OR=1.17 (1.04–1.31)) and
rs7747909 (p=0.042, OR=1.14 (1.01–1.29)) and GCA. A
clear trend of association was also observed for rs4711998
(p=0.055, OR=1.13 (1.00–1.28)) and rs8193036 (p=0.063,
OR=1.13 (0.99–1.29)). Permutation testing did not signiﬁcantly
affect the observed results (PEMP1=0.055, PEMP1=0.057,
PEMP1=0.429, PEMP1=0.011 and PEMP1=0.041, for rs4711998,
rs8193036, rs3819024, rs2275913 and rs7747909, respect-
ively). After applying the more stringent corrected permutation
p values, rs2275913 remained signiﬁcantly associated with GCA
(PEMP2=0.041). Subsequently, no speciﬁc genetic association
with any of the analysed clinical forms was detected (data not
shown).
To better explore the results observed in the Spanish cohort,
IL17A polymorphisms were then analysed in three independent
cohorts of European ancestry (see online supplementary table
S3). Data from the discovery and replication cohorts were com-
bined in order to elucidate the role of IL17A in GCA (BD test:
p>0.05). As shown in table 2, the overall meta-analysis showed
a clear association of rs2275913*A (PMH=1.85E–03, OR=1.17
(1.06–1.29)) and rs7747909*A (PMH=8.49E–03, OR=1.15
(1.04–1.27)) with GCA. A trend of association was also
observed for the rs4711998*A variant (PMH=0.059, OR=1.11
(1.00–1.23)).
Conditional logistic regression
As shown in table 3, the association observed for rs7747909
was dependent of rs2275913, maybe due to the moderate
linkage disequilibrium between them (r2 ∼ 0.59) (see online
supplementary ﬁgure S1). However, for rs4711998, a trend of
association was still evident after conditioning by the other two
polymorphisms.
Haplotype analysis
Two haplotypes were associated with GCA (see online supplemen-
tary ﬁgure S1 and table S4), a risk haplotype harbouring the minor
alleles of the analysed polymorphisms (rs4711998*A/rs8193036*C/
rs3819024*G/rs2275913*A/rs7747909*A: p=0.021, OR=1.38
(1.06–1.79)) and a protective haplotype containing the major alleles
Table 1 Genotype and allele distribution of the IL17A genetic variants in Spanish biopsy-proven GCA patients and healthy controls
Genotype, N (%) Allele test
SNP 1/2 Subgroup (N) 1/1 1/2 2/2 MAF (%) p Value* PEMP2† OR (95% CI)‡
rs4711998 A/G Controls (n=1769) 127 (7.18) 688 (38.89) 954 (53.93) 26.63
GCA (n=916) 79 (8.62) 375 (40.94) 462 (50.44) 29.09 0.0547 0.196 1.13 (1.00 to 1.28)
rs8193036 C/T Controls (n=1814) 82 (4.52) 647 (35.67) 1085 (59.81) 22.35
GCA (n=923) 47 (5.09) 360 (39.00) 516 (55.90) 24.59 0.0631 0.224 1.13 (0.99 to 1.29)
rs3819024 G/A Controls (n=1827) 197 (10.78) 815 (44.61) 815 (44.61) 33.09
GCA (n=915) 100 (10.93) 425 (46.45) 390 (42.62) 34.15 0.4301 0.894 1.05 (0.93 to 1.18)
rs2275913 A/G Controls (n=1815) 197 (10.85) 801 (44.13) 817 (45.01) 32.92
GCA (n=908) 116 (12.78) 429 (47.25) 363 (39.98) 36.40 0.0107 0.041 1.17 (1.04 to 1.31)
rs7747909 A/G Controls (n=1820) 137 (7.53) 709 (38.96) 974 (53.52) 27.01
GCA (n=920) 73 (7.93) 399 (43.37) 448 (48.70) 29.62 0.0416 0.153 1.14 (1.01 to 1.29)
Significant p values are shown in bold.
*All p values have been calculated for the allelic model.
†p Values based on 10 000 permutations and corrected for multiple testing.
‡OR for the minor allele.
GCA, giant cell arteritis; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
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of these SNPs (rs4711998*G/rs8193036*T/rs3819024*A/
rs2275913*G/rs7747909*G: p=0.048, OR=0.91 (0.83–1.00)).
We observed a statistically signiﬁcant improvement of the
goodness of ﬁt of the allelic combination model compared with
that including rs4711998 (likelihood p value=8.38×10−06),
rs2275913 (likelihood p value=3.60×10−05) or rs7747909
(likelihood p value=3.49×10−05) individually.
DISCUSSION
Our data show for the ﬁrst time an association between poly-
morphisms at the IL17A gene and GCA. The pooled analysis of
four European cohorts evidenced three SNPs (rs4711998,
rs2275913 and rs7747909) conferring risk to GCA, with
rs2275913 showing the strongest association. Interestingly, this
polymorphism is located within a binding motif for the nuclear
factor activated T cells (NFAT), a central regulator of the IL-17
promoter.14 Consistent with our results, showing an increased
frequency of the rs2275913*A allele in GCA patients compared
with controls, it has been recently proposed that this allele leads
to a higher afﬁnity for NFAT that correlates with an increase of
the IL-17A secretion.15 This observation would agree with the
elevated levels of IL-17A found in inﬂammatory lesions of
patients with GCA.3 6
Our results are in line with those previously reported in
rheumatoid arthritis (RA),13 which show a stronger effect for
rs2275913. Moreover, the effect size detected in our study is
consistent with the weak effect described in patients with RA
(OR=1.17). Due to the proposed functional role for
rs2275913, this polymorphism was considered as a putative
candidate to be responsible of the detected association between
IL17A and RA.13 However, our results suggest the existence of
several independent signals in GCA. Accordingly with this idea,
several polymorphisms in IL17A, in addition to rs2275913,
have been found to inﬂuence binding afﬁnity with transcription
factor complexes, IL-17A levels and methylation status of the
IL17A promoter in inﬂammatory bowel disease patients,16 thus
supporting the possible presence of different genetic variants
with independent functional consequences.
The immunopathogenesis of GCA is mainly driven by two
separate lineages of CD4 T cells, Th1, which seem to play a
more important role in chronic disease, and Th17, which
appear to have a relevant implication in early disease.8 Although
the role of Th1 cytokines and their receptors, such as IFN-γ,
IL-18 and IL12RB2, in the susceptibility to GCA has been more
clearly demonstrated,10 evidences of the inﬂuence of cytokines
involved in Th17 responses in this vasculitis predisposition have
also emerged during the last years. Interestingly, a role of IL6
and IL21, involved in promoting the differentiation of Th17
cells, has been reported in several genetic studies.17 18 Our
results, together with these previous ﬁndings, support a crucial
involvement of Th17 cells in GCA and ﬁrmly implicate the
IL6-IL17 cytokine cluster in its susceptibility.
On the other hand, it should be highlighted the important
role of IL-17A as a proatherogenic factor.19 It has been reported
that pre-existing atherosclerosis represents a potential risk factor
for ischaemic manifestations in GCA.20 It is therefore plausible
that this cytokine might also affect the severity of this vasculitis,
thus representing an attractive therapeutic target for GCA.
In summary, our study provides clear evidence of the role of
IL17A as a genetic risk locus for GCA, thus contributing to the
advance in the knowledge of the genetic network underlying
this vasculitis susceptibility. Functional studies are required in
order to clarify the responsible variant/s of this association and
its functional consequences.
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